title: [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
abstract: OBJECTIVE
  As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients with advanced non-small cell lung cancer (NSCLC) compared with gefitinib. This retrospective study aims to evaluate the efﬁcacy and tolerability of icotinib monotherapy for advanced NSCLC patients with EGFR mutation and wild-type patients in our hospital.
  
  
  METHODS
  Patients with advanced NSCLC who were treated with icotinib in Zhejiang Cancer Hospital were retrospectively analyzed from August, 2011 to August, 2012. Survival was estimated using Kaplan-Meier analysis and Log-rank tests.
  
  
  RESULTS
  The clinical data of 49 patients (13 with wild-type and 36 with EGFR mutation) with NSCLC were enrolled in the current study. The patients' overall objective response rate (ORR) was 58.3% and the disease control rate (DCR) in 36 EGFR mutation patients was 88.9%. The ORR was 7.7% and DCR was 53.8% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 9.5 months and 2.2 months in wild-type patients (P<0.001). Nineteen patients with EGFR mutation received icotinib as first-line and 17 in further-line treatment. The PFS was 9.5 months in the first-line and 8.5 months for second-line or further-line patients (P=0.41). Median overall survival (OS) in EGFR mutation patients was not reached, but was 12.6 months in wild-type patients. Most of the drug-related adverse events were mild (grade I or II) and reversible with no grade IV toxicity.
  
  
  CONCLUSIONS
  Icotinib monotherapy showed signiﬁcant antitumor activity in advanced NSCLC EGFR mutation patients. The toxicity was well tolerated and acceptable.
authors.affiliation: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Zhengbo
authors.initials: Z
authors.lastname: Song
authors.forename: Xinmin
authors.initials: X
authors.lastname: Yu
authors.forename: Jufen
authors.initials: J
authors.lastname: Cai
authors.forename: Lan
authors.initials: L
authors.lastname: Shao
authors.forename: Baochai
authors.initials: B
authors.lastname: Lin
authors.forename: Chunxiao
authors.initials: C
authors.lastname: He
authors.forename: Beibei
authors.initials: B
authors.lastname: Zhang
authors.forename: Yiping
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D043844:Crown Ethers / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D012189:Retrospective Studies; D012449:Safety; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib; C512478:EGFR protein, human; D066246:ErbB Receptors